Cancer BiologybioRxivPreprint
Neutralizing PD-L1 and PD-L2 Enhances the Efficacy of Immune Checkpoint Inhibitors in Ovarian Cancer.
Y. R. Miao, K. N. Thakkar, J. Qian…·A. J. Giaccia
The paper develops a high-affinity sPD-1 decoy molecule that neutralizes both PD-L1 and PD-L2, showing superior antitumor activity in ovarian cancer models compared to PD-1/PD-L1 antibodies.
DOI 10.1101/2020.01.19.911941